X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8270) 8270
Book Review (802) 802
Publication (718) 718
Magazine Article (17) 17
Conference Proceeding (14) 14
Book Chapter (9) 9
Dissertation (5) 5
Book / eBook (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7786) 7786
humans (5530) 5530
male (4596) 4596
animals (3726) 3726
female (3447) 3447
pyrroles - administration & dosage (2792) 2792
pyrroles - pharmacology (2593) 2593
pyrroles - therapeutic use (2512) 2512
atorvastatin calcium (2430) 2430
middle aged (2347) 2347
aged (1733) 1733
mice (1598) 1598
rats (1551) 1551
adult (1524) 1524
pharmacology & pharmacy (1485) 1485
oncology (1355) 1355
heptanoic acids - administration & dosage (1352) 1352
treatment outcome (1295) 1295
pyrroles - adverse effects (1128) 1128
heptanoic acids - therapeutic use (1106) 1106
atorvastatin (1091) 1091
dose-response relationship, drug (1065) 1065
cancer (1000) 1000
sunitinib (906) 906
indoles - therapeutic use (905) 905
indoles - administration & dosage (891) 891
statins (888) 888
abridged index medicus (879) 879
heptanoic acids - pharmacology (754) 754
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (750) 750
analysis (728) 728
care and treatment (685) 685
carcinoma, renal cell - drug therapy (656) 656
cardiac & cardiovascular systems (653) 653
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (650) 650
drug therapy (642) 642
antineoplastic agents - therapeutic use (640) 640
research (630) 630
cholesterol (628) 628
expression (616) 616
kidney neoplasms - drug therapy (613) 613
time factors (606) 606
disease models, animal (571) 571
therapy (569) 569
indoles - adverse effects (559) 559
pyrroles - pharmacokinetics (555) 555
indoles - pharmacology (551) 551
cell line, tumor (509) 509
rats, sprague-dawley (503) 503
drug administration schedule (496) 496
cholesterol, ldl - blood (489) 489
inflammation (487) 487
simvastatin (480) 480
anticholesteremic agents - administration & dosage (478) 478
drug therapy, combination (478) 478
double-blind method (476) 476
aged, 80 and over (474) 474
administration, oral (469) 469
pyrroles - chemistry (468) 468
neurosciences (459) 459
risk factors (443) 443
antineoplastic agents - administration & dosage (439) 439
pyrimidines - therapeutic use (439) 439
pyrimidines - pharmacology (435) 435
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (428) 428
anticholesteremic agents - therapeutic use (427) 427
biochemistry & molecular biology (427) 427
tyrosine kinase inhibitor (426) 426
medicine & public health (423) 423
article (416) 416
rats, wistar (415) 415
endothelial growth-factor (409) 409
mice, inbred c57bl (409) 409
rodents (409) 409
efficacy (407) 407
immunology (407) 407
in-vivo (399) 399
kidney neoplasms - pathology (398) 398
pyrimidines - administration & dosage (393) 393
angiogenesis (386) 386
health aspects (385) 385
niacinamide - analogs & derivatives (384) 384
indoleamine-pyrrole 2,3,-dioxygenase - metabolism (374) 374
atherosclerosis (373) 373
heptanoic acids - adverse effects (371) 371
metastasis (365) 365
antineoplastic agents (361) 361
pyrroles (360) 360
inhibition (358) 358
antineoplastic agents - adverse effects (357) 357
tumors (356) 356
peripheral vascular disease (352) 352
hypercholesterolemia - drug therapy (350) 350
apoptosis (347) 347
disease (344) 344
antimitotic agents (342) 342
prospective studies (332) 332
retrospective studies (332) 332
proteins (330) 330
antineoplastic agents - pharmacology (325) 325
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7995) 7995
German (76) 76
Japanese (46) 46
Russian (40) 40
French (32) 32
Italian (25) 25
Chinese (23) 23
Spanish (19) 19
Hungarian (8) 8
Polish (7) 7
Swedish (6) 6
Czech (5) 5
Ukrainian (5) 5
Danish (2) 2
Korean (2) 2
Lithuanian (2) 2
Norwegian (2) 2
Croatian (1) 1
Dutch (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 9, pp. 1140 - 1146
Three-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are first-line treatments for hypercholesterolemia. Although exceedingly well... 
CLARITHROMYCIN | INDUCED RHABDOMYOLYSIS | LOVASTATIN | CARDIAC & CARDIOVASCULAR SYSTEMS | CONCOMITANT USE | ERYTHROMYCIN | FATAL RHABDOMYOLYSIS | ITRACONAZOLE | ROSUVASTATIN | DRUG-INTERACTION | CYCLOSPORINE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 Enzyme System - administration & dosage | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Mibefradil - pharmacokinetics | Male | Protein Synthesis Inhibitors - administration & dosage | Verapamil - administration & dosage | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Antiprotozoal Agents - pharmacokinetics | Drug Interactions | Itraconazole - pharmacokinetics | Pyrroles - administration & dosage | Clarithromycin - pharmacokinetics | Mibefradil - administration & dosage | Clarithromycin - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Itraconazole - administration & dosage | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Verapamil - pharmacokinetics | Biomarkers - blood | Simvastatin - pharmacokinetics | Protein Synthesis Inhibitors - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Antiprotozoal Agents - administration & dosage | Calcium Channel Blockers - administration & dosage | Creatine Kinase - drug effects | Calcium Channel Blockers - pharmacokinetics | Pravastatin - pharmacokinetics | Index Medicus | Abridged Index Medicus
Journal Article
Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Index Medicus | Abridged Index Medicus | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | RANDOMIZED-TRIAL | ETANERCEPT | CLINICAL-OUTCOMES | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | E.S.R | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Drug therapy | Pharmaceuticals | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
Analytical and Bioanalytical Chemistry, ISSN 1618-2642, 4/2018, Volume 410, Issue 11, pp. 2815 - 2828
Generation of skin distribution profiles and reliable determination of drug molecule concentration in the target region are crucial during the development... 
Biochemistry, general | Skin penetration | Food Science | Quantification | Drug distribution | Mass spectrometry imaging | Human skin | Laboratory Medicine | MALDI-MSI | Chemistry | Analytical Chemistry | Monitoring/Environmental Analysis | Characterization and Evaluation of Materials | CHEMISTRY, ANALYTICAL | HUMAN STRATUM-CORNEUM | BIOCHEMICAL RESEARCH METHODS | PENETRATION | MOLECULAR-SIZE | MICROSCOPY | MASS-SPECTROMETRY | TISSUE-SECTIONS | ATOPIC-DERMATITIS | PERCUTANEOUS-ABSORPTION | PSORIASIS | Pyrroles - pharmacokinetics | Benzamides - pharmacokinetics | Skin - metabolism | Humans | Aminopyridines - pharmacokinetics | Pyridines - pharmacokinetics | Drug Discovery - methods | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Pyrroles - administration & dosage | Piperidines - pharmacokinetics | Pyrazoles - pharmacokinetics | Cyclopropanes - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Aminopyridines - administration & dosage | Piperidines - administration & dosage | Pyridines - administration & dosage | Acetamides - pharmacokinetics | Phosphodiesterase 4 Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Skin Absorption | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Pyrimidines - pharmacokinetics | Administration, Topical | Acetamides - administration & dosage | Pharmaceutical research | Topical medication | Pharmaceutical industry | Innovations | Testing | Formulations | Explants | Psoriasis | Medical treatment | Spatial discrimination | Imaging techniques | Ions | Mass spectroscopy | Desorption | Drug development | Tissues | Dermatitis | Ionization | Lasers | Atopic dermatitis | Imaging | Skin diseases | Skin | Mass spectrometry | Spatial resolution | Physicochemical properties | Index Medicus
Journal Article
European Neuropsychopharmacology, ISSN 0924-977X, 11/2018, Volume 28, Issue 11, pp. 1247 - 1259
Endocannabinoids and their receptors not only contribute to the control of natural processes of appetite regulation and energy balance but also have an... 
Appetite regulation | Gamma-aminobutyric acid | Cannabinoids | CB1 | Serotonin | Paraventricular hypothalamic nucleus | POMC NEURONS | ENDOGENOUS CANNABINOIDS | HYPERPHAGIA | PSYCHIATRY | ENDOCANNABINOID SYSTEM | NEUROSCIENCES | CLINICAL NEUROLOGY | NEUROPEPTIDE-Y | BODY-WEIGHT | OBESITY | CANNABINOID RECEPTOR | INHIBITION | PHARMACOLOGY & PHARMACY | AUTORADIOGRAPHY | Piperazines - administration & dosage | Cyproheptadine - administration & dosage | Serotonin - administration & dosage | Serotonin Antagonists - administration & dosage | Receptors, Serotonin, 5-HT1 - physiology | gamma-Aminobutyric Acid - metabolism | Amphetamines - pharmacology | Spiro Compounds - administration & dosage | Male | Amphetamines - administration & dosage | Serotonin - pharmacology | Receptor, Cannabinoid, CB1 - physiology | Eating - physiology | Serotonin Receptor Agonists - pharmacology | Cyproheptadine - pharmacology | Drug Interactions | Receptor, Cannabinoid, CB1 - agonists | Tritium - metabolism | Piperidines - pharmacology | Pyrroles - administration & dosage | Pyrazoles - pharmacology | Piperidines - administration & dosage | Pyridines - administration & dosage | Microinjections | Rats | 8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology | Piperidones - pharmacology | Serotonin Antagonists - pharmacology | Piperazines - pharmacology | Arachidonic Acids - pharmacology | Piperidones - administration & dosage | Pyrazoles - administration & dosage | Pyrroles - pharmacology | 8-Hydroxy-2-(di-n-propylamino)tetralin - administration & dosage | Animals | Serotonin - metabolism | Paraventricular Hypothalamic Nucleus - metabolism | Pyridines - pharmacology | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Serotonin Receptor Agonists - administration & dosage | Spiro Compounds - pharmacology | GABA | Control systems | RNA | Neurophysiology | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10032, pp. 2008 - 2016
Journal Article